NIAID’s Klebsiella Bacteria Research

Agency: 
Dept. of Health and Human Services

Photo credit: NIAID

NIAID researchers are developing a promising alternative to antibiotic treatment for infections caused by Klebsiella pneumoniae bacteria resistant to carbapenem antibiotics. Antibodies target the K. pneumoniae protective capsule polysaccharide, allowing neutrophils to attack and kill the bacteria. In the early stage, in vitro research was conducted at NIAID’s Rocky Mountain Laboratories and the New Jersey Medical School – Rutgers University.  Klebsiella bacteria cause about 10 percent of all hospital-acquired infections in the United States. A carbapenem-resistant K. pneumoniae strain, multilocus sequence type 258 (ST258), is one of the antibiotic-resistant organisms labeled an urgent threat by the Centers for Disease Control and Prevention.

NIAID’s Laboratory of Bacteriology (LB) studies bacteria that cause important human infections, including intracellular and arthropod-borne bacterial pathogens. The Lab conducts research with antibiotic-resistant bacteria listed as serious or urgent threats in the National Action Plan for Combating Antibiotic-Resistant Bacteria. The ultimate goal for the research is to identify novel or improved strategies to control bacterial diseases, including the development of diagnostics, vaccines, and therapeutics.

To learn more about NIAID, visit the profile on FLC Business.

Category: 
Lab Spotlight
Region: 
Mid-Atlantic